查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924696

按劑型、規格、包裝、用途、通路和最終用戶分類的通用名Lurasidone學名藥市場—2026-2032年全球預測

Lurasidone Hydrochloride Generics Market by Form, Strength, Packaging Type, Application, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，鹽酸Lurasidone學名藥市場價值為 8.9592 億美元，預計到 2026 年將成長至 9.8524 億美元，到 2032 年將達到 18.4048 億美元，複合年成長率為 10.83%。

關鍵市場統計數據
基準年 2025 8.9592億美元
預計年份：2026年 9.8524億美元
預測年份 2032 1,840,480,000 美元
複合年成長率 (%) 10.83%

本文簡要概述了影響鹽酸魯拉西酮Lurasidone學名藥的臨床應用、監管途徑和商業性需求。

本執行摘要探討了影響學名藥Lurasidone學名藥市場的競爭格局和臨床現狀，該藥物在現代精神疾病治療策略中扮演著日益重要的角色。摘要對專利到期、監管路徑和生產複雜性進行了綜合分析，並將該化合物置於更廣泛的情緒障礙和精神病治療框架中。透過重點關注臨床適應症、劑型、通路和終端用戶趨勢，概要為生產者、經銷商和相關人員的策略決策提供了基礎。

分析不斷發展的臨床證據、監管預期和生產創新如何重塑Lurasidone學名藥的競爭格局

受臨床需求、不斷變化的監管法規和生產製程創新等因素的共同驅動，學名藥的市場環境Lurasidone經歷著變革性的變化。臨床上，其在思覺失調症方面的確切效用，以及在重度憂鬱症和躁鬱症方面療效日益增強的證據，正在改變處方模式，並促使支付方和臨床醫生更加嚴格地評估其成本效益和治療替代性。同時，監管機構正在完善生物等效性要求和核准後藥物警戒要求，這正在推動研發時間表和生命週期管理策略的調整。

需要對 2025 年關稅變化及其對學名藥供應鏈韌性籌資策略和商業營運的連鎖影響進行冷靜評估。

2025年公佈的政策決定和關稅調整為醫藥原料和製劑的生產商和經銷商帶來了新的成本和營運方面的考量。某些活性藥物成分和中間體化學品的進口關稅提高，加劇了依賴全球獨立供應鏈的企業對投入成本的敏感度。為此，一些生產商正在加快供應商多元化，推進本地化籌資策略，並簽訂長期契約，以降低關稅波動帶來的風險。這些調整將影響前置作業時間、庫存計劃和利潤管理。

深入的細分市場分析展示了臨床適應症、製劑強度、通路、終端用戶和包裝選擇對商業和營運策略的影響。

細分市場層面的差異化是理解競爭優勢所在的關鍵，這體現在治療領域和產品劑型兩方面。在同一治療領域內，必須牢記雙極性情感障礙、重度憂鬱症和思覺失調症之間的臨床差異，因為這些適應症的處方習慣和報銷途徑截然不同。劑型的選擇，例如一般片劑與口崩壞片，會影響患者的依從性和給藥方式，進而影響產品在門診和住院環境中的定位。

區域市場動態和監管差異影響市場進入和供應策略。美洲、歐洲、中東和非洲以及亞太地區的區域市場動態和監管差異會影響市場進入和供應策略。

區域趨勢在商業規劃和監管策略中發揮著至關重要的作用，美洲、歐洲、中東和非洲以及亞太地區呈現出截然不同的模式。在美洲，支付方結構和處方集管理實踐往往側重於成本效益和治療替代，從而影響合約簽訂方式和回扣談判。病患准入計畫和與專科藥局的合作也影響精神科藥物的供應。各國監管機構之間的監管協調以及促進國內生產的政策，對於供應連續性和定價策略而言，正日益成為重要的考量。

公司層面的競爭和營運洞察突顯了推動學名藥，包括監管應對力、生產能力和分銷通路夥伴關係。

製造商和商業夥伴之間的競爭地位取決於其在監管申報、生產品質和分銷管道方面的能力。主要企業憑藉著完善的生物等效性文件、支援多種劑型和劑量的適應性生產流程，以及與經銷商建立的策略聯盟（確保產品進入醫院、零售藥局和線上藥局），從而脫穎而出。投資於病患支援服務、依從性計畫和臨床醫生教育的企業，能夠創造價格之外的顯著價值，這在競爭性競標和處方集評估中日益重要。

為製造商和經銷商提供切實可行的策略建議，重點關注強力的採購、基於證據的合作以及針對特定管道的商業化，以最大限度地發揮影響力。

尋求永續競爭優勢的行業領導者應專注於三個相互關聯的優先事項：增強供應鏈韌性、深化與臨床試驗機構和支付方的合作以及針對特定管道的商業化。透過建立多通路關鍵物料來源、策略性庫存緩衝以及檢驗的二級供應商來強化供應鏈，可以降低受關稅衝擊和物流中斷的影響。同時，投資於全面的監管計劃和健全的生物等效性項目，可以加快核准流程，並有助於產品進入具有不同證據要件的市場。

對多源研究途徑的透明解釋：結合相關人員訪談、監管審查和管道分析，檢驗研究結果和見解。

本研究整合了透過相關人員訪談、監管審查和管道分析收集的一手和二手訊息，全面展現了Lurasidone學名藥的市場格局。一手資訊包括對臨床醫生、藥劑師和供應鏈專家的結構化訪談，旨在了解處方行為、配藥模式和採購機制。二手資訊包括監管指導文件、已發表的臨床證據和公共政策聲明，以闡明監管和報銷背景，並確保結論符合現行標準。

一項嚴謹的審查，重申了關鍵的臨床、監管和營運重點以及實現持續商業性成功的策略路徑。

總之，Lurasidone學名藥學名藥的競爭格局是由臨床差異、監管嚴格性和營運複雜性共同塑造的。在雙極性情感障礙、重度憂鬱症和思覺失調症等適應症中，臨床差異化需要與處方醫生進行有針對性的溝通，並提供個人化的證據資訊。生物等效性和上市後監測的監管要求需要謹慎用藥和藥物警戒，而靈活的劑型和劑量生產能力則有助於應對力。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 鹽酸Lurasidone學名藥市場按劑型分類

  • 口溶錠
  • 藥片

9. 鹽酸Lurasidone學名藥市場（依規格分類）

  • 20 mg
  • 40mg
  • 60mg
  • 80mg

第10章 鹽酸Lurasidone酮學名藥市場（以包裝形式分類）

  • 泡殼包裝
  • 瓶子

第11章 按應用分類的通用Lurasidone學名藥市場

  • 雙相情感障礙相關的憂鬱症
  • 重度憂鬱症
  • 思覺失調症

第12章 鹽酸Lurasidone學名藥市場（依通路分類）

  • 離線
  • 線上

第13章 鹽酸Lurasidone學名藥市場（依最終用戶分類）

  • 診所
  • 居家照護設施
  • 醫院

第14章 各地區Lurasidone酮學名藥市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 鹽酸Lurasidone學名藥市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國Lurasidone酮學名藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國通用Lurasidone學名藥市場

第18章：中國仿製學名藥Lurasidone酮市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accord Healthcare
  • Alembic Pharmaceuticals
  • Alkem Laboratories
  • Amneal Pharmaceuticals
  • Annora Pharma
  • Aurobindo Pharma
  • Camber Pharmaceuticals
  • Chartwell Rx
  • Cipla
  • Dr. Reddy's Laboratories
  • Emcure Pharmaceuticals
  • Heritage Pharma Avet
  • Icon Life Sciences
  • Intas Pharmaceuticals
  • Invagen Pharmaceuticals
  • Jubilant Generics
  • Linux Laboratories
  • Lupin
  • Macleods Pharmaceuticals
  • MSN Laboratories
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Torrent Pharmaceuticals
  • Zydus Pharmaceuticals
Product Code: MRR-7A380DA7C432

The Lurasidone Hydrochloride Generics Market was valued at USD 895.92 million in 2025 and is projected to grow to USD 985.24 million in 2026, with a CAGR of 10.83%, reaching USD 1,840.48 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 895.92 million
Estimated Year [2026] USD 985.24 million
Forecast Year [2032] USD 1,840.48 million
CAGR (%) 10.83%

A concise orienting overview that frames clinical uses regulatory pathways and commercial imperatives shaping the lurasidone hydrochloride generics environment

This executive summary introduces the competitive and clinical landscape shaping lurasidone hydrochloride generics, a category increasingly central to modern psychiatric therapeutic strategies. The narrative synthesizes patent expirations, regulatory pathways, and manufacturing complexity while situating the compound within broader treatment paradigms for mood and psychotic disorders. By focusing on clinical indications, dosage formulations, distribution channels, and end-user patterns, the introduction sets the stage for strategic decision-making by manufacturers, distributors, and clinical stakeholders.

Beyond basic characterization, the introduction emphasizes how evolving prescriber preferences and payer frameworks influence generic adoption. It highlights the importance of quality-by-design in manufacturing, the role of bioequivalence studies in regulatory approvals, and the operational considerations around packaging and distribution. The aim is to provide an accessible yet rigorous foundation that enables readers to navigate subsequent sections with a clear understanding of the key drivers, constraints, and opportunities that define the current generics environment for lurasidone hydrochloride.

An analysis of how evolving clinical evidence regulatory expectations and manufacturing innovations are reshaping the competitive dynamics of lurasidone generics

The lurasidone generics landscape is undergoing transformative shifts driven by convergence of clinical demand, regulatory evolution, and manufacturing innovation. Clinically, expanded evidence for efficacy in major depressive disorder and bipolar depression alongside established utility in schizophrenia has altered prescribing patterns, prompting payers and clinicians to evaluate cost-effectiveness and therapeutic interchangeability more closely. Concurrently, regulatory authorities are refining bioequivalence expectations and post-approval pharmacovigilance requirements, which is reshaping development timelines and lifecycle management strategies.

On the supply side, advancements in formulation science, particularly in orally disintegrating tablet technologies, are enabling competitive differentiation even within a generics marketplace. Parallel improvements in contract manufacturing and supply chain digitization are reducing lead times and improving traceability, yet they also expose manufacturers to geopolitical and input-cost volatility. Taken together, these shifts are driving manufacturers to prioritize robust regulatory dossiers, scalable quality systems, and channel-specific commercialization plans that account for both clinical nuance and operational resilience.

A clear-eyed assessment of the 2025 tariff changes and their cascading effects on supply chain resilience sourcing strategies and commercial operations for generics

Policy decisions and tariff adjustments announced in 2025 have introduced new cost and operational considerations for manufacturers and distributors of pharmaceutical ingredients and finished dosage forms. Increased import duties on select active pharmaceutical ingredients and intermediate chemicals have raised input-cost sensitivity for companies that rely on globalized supply chains. In response, several manufacturers have accelerated supplier diversification, localized sourcing strategies, and long-term contracting to mitigate exposure to ad hoc tariff fluctuations. These adjustments have implications for lead times, inventory planning, and margin management.

In parallel, logistics and customs processing times have become a focal point for commercial planning as companies seek to avoid bottlenecks that exacerbate cost pressures. Regulatory agencies and industry associations have responded by emphasizing transparency in supply chains and by encouraging pre-clearance and tariff classification alignment to reduce clearance delays. The net effect of these tariff-related developments is not uniform across the sector; enterprises with integrated manufacturing capabilities and flexible sourcing are better positioned to absorb incremental costs, while smaller players are exploring partnerships and contract manufacturing arrangements to stabilize supply and preserve competitive pricing.

Insightful segmentation analysis demonstrating how clinical indications formulations strengths channels end-users and packaging choices influence commercial and operational strategy

Segment-level distinctions are central to understanding where competitive advantage can be established across therapeutic application and product presentation. Within therapeutic application, attention must be paid to clinical differentiation across bipolar depression, major depressive disorder, and schizophrenia because prescribing routines and reimbursement pathways vary significantly among these indications. Formulation choices such as standard tablets versus orally disintegrating tablets introduce different patient adherence and administration considerations, which in turn affect product positioning for outpatient and institutional use.

Strength variations spanning 20 mg, 40 mg, 60 mg, and 80 mg require manufacturers to plan manufacturing flexibility and inventory strategies that can accommodate dose titration and switching. Distribution channel complexity encompasses hospital pharmacy settings-both general pharmacies and psychiatric units-online pharmacy models that include proprietary and third-party platforms, and retail outlets divided between chain and independent pharmacies; each channel has distinct procurement cycles, margin expectations, and promotional levers. End-user segmentation across clinics with day care and outpatient models, home care settings that rely on caregiver or self-administration, and hospitals differentiated by general and psychiatric facilities informs outreach, packaging, and patient support strategies. Packaging type choices between blister and bottle affect stability, dispensing accuracy, and patient convenience, and therefore should be aligned with channel and end-user preferences to optimize uptake and adherence.

Regional market dynamics and regulatory nuances across the Americas Europe Middle East & Africa and Asia-Pacific that influence market access and supply strategies

Regional dynamics play a decisive role in commercial planning and regulatory strategy, with distinctive patterns emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, payer structures and formulary management practices tend to emphasize cost-effectiveness and therapeutic substitution, influencing contracting approaches and rebate negotiation; patient access programs and specialty pharmacy partnerships also shape uptake for psychiatric therapies. Regulatory harmonization between national authorities and incentivized domestic manufacturing initiatives are increasingly relevant considerations for supply continuity and pricing strategy.

In Europe Middle East & Africa, diverse regulatory regimes and varying levels of healthcare infrastructure create a mosaic of market access pathways. Centralized regulatory procedures in some jurisdictions coexist with country-level reimbursement decisions, prompting tailored dossiers and localized HEOR narratives. In the Asia-Pacific region, rapid growth in outpatient care and expanding digital pharmacy ecosystems are changing distribution models, while regional manufacturing capabilities and supply integration present both opportunities for cost optimization and risks tied to raw material sourcing. Navigating these regional idiosyncrasies requires calibrated market-entry strategies and adaptive channel management.

Competitive and operational company-level observations highlighting regulatory strengths manufacturing capabilities and channel partnerships that drive differentiation in generics

Competitive positioning among manufacturers and commercial partners hinges on capabilities across regulatory filings, manufacturing quality, and channel distribution. Leading companies differentiate through robust bioequivalence dossiers, adaptive manufacturing processes that support multiple strengths and formulations, and strategic alliances with distributors that secure hospital, retail, and online pharmacy placements. Firms that invest in patient support services, adherence programs, and clinician education can create perceptible value beyond price, which is increasingly important in competitive tenders and formulary evaluations.

Moreover, organizations that can integrate pharmacovigilance feedback with post-market evidence collection are better positioned to sustain trust among prescribers and payers. Contract manufacturing organizations that offer scalable capacity and regulatory-compliant facilities are strategic partners for companies that lack vertically integrated production. Finally, partnerships that enable streamlined supply to psychiatric units and specialized clinics, as well as digital-first distribution agreements with proprietary and third-party online pharmacies, amplify reach and responsiveness to evolving clinical and channel demand.

Actionable strategic recommendations for manufacturers and distributors focusing on resilient sourcing evidence-driven engagement and channel-tailored commercialization to maximize impact

Industry leaders seeking durable advantage should focus on three interlocking priorities: supply chain resilience, clinical and payer engagement, and channel-specific commercialization. Strengthening supply chains through multi-sourcing of critical inputs, strategic inventory buffers, and validated secondary suppliers reduces vulnerability to tariff shocks and logistical disruption. Concurrently, investing in comprehensive regulatory planning and robust bioequivalence programs will accelerate approvals and facilitate market entry across jurisdictions with varying evidentiary expectations.

On the commercial front, tailored engagements with clinicians and payers that emphasize real-world adherence benefits, comparative tolerability data, and support services can shift procurement decisions beyond unit price. Channel strategies must be granular, recognizing the differing needs of hospital pharmacy settings including psychiatric units, online pharmacy platforms whether proprietary or third-party, and retail environments across chain and independent pharmacies. Finally, consider packaging and patient-support innovations that align with end-user realities in clinics, home care settings, and hospitals to improve adherence and clinical outcomes while enhancing product differentiation.

Transparent explanation of the multi-source research approach combining stakeholder interviews regulatory review and channel analysis to validate findings and insights

This research synthesizes primary and secondary intelligence gathered through stakeholder interviews, regulatory review, and channel analyses to produce a holistic view of the lurasidone generics environment. Primary inputs included structured interviews with clinicians, pharmacists, and supply chain specialists to capture prescriber behavior, dispensing patterns, and procurement mechanics. Secondary inputs comprised regulatory guidance documentation, published clinical evidence, and public policy statements to inform regulatory and reimbursement context while ensuring that conclusions are consistent with current standards.

Analytical methods emphasized cross-validation of findings across sources and triangulation between clinical practice insights and distribution behavior. Quality controls included validation of clinical claims against peer-reviewed literature and verification of distribution patterns through interviews with pharmacy operations personnel. The methodological approach prioritized transparency in assumptions and clear documentation of data sources and limitations, thereby enabling readers to assess the robustness of conclusions and to replicate key analytic steps for localized decision-making.

A rigorous concluding synthesis that reiterates clinical regulatory and operational imperatives and the strategic pathways to sustained commercial success

In conclusion, the competitive landscape for lurasidone hydrochloride generics is shaped by a confluence of clinical nuance, regulatory rigor, and operational complexity. Clinical differentiation across indications such as bipolar depression major depressive disorder and schizophrenia requires targeted engagement with prescribers and tailored evidence communication. Regulatory expectations for bioequivalence and post-market surveillance necessitate careful dossier preparation and pharmacovigilance readiness, while manufacturing flexibility across strengths and formulation types supports responsiveness to clinical dosing patterns.

Distribution and end-user segmentation-from hospital pharmacies and psychiatric units to online and retail channels and from clinics to home care settings-requires channel-specific strategies that align packaging, support services, and inventory practices with actual dispensing and administration contexts. Strategic investments in supply chain resilience and partnerships that bridge manufacturing, clinical outreach, and digital distribution will be decisive for organizations aiming to secure trusted positions within this evolving generics market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lurasidone Hydrochloride Generics Market, by Form

  • 8.1. Orally Disintegrating Tablet
  • 8.2. Tablet

9. Lurasidone Hydrochloride Generics Market, by Strength

  • 9.1. 20 mg
  • 9.2. 40 mg
  • 9.3. 60 mg
  • 9.4. 80 mg

10. Lurasidone Hydrochloride Generics Market, by Packaging Type

  • 10.1. Blister
  • 10.2. Bottle

11. Lurasidone Hydrochloride Generics Market, by Application

  • 11.1. Bipolar Depression
  • 11.2. Major Depressive Disorder
  • 11.3. Schizophrenia

12. Lurasidone Hydrochloride Generics Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Lurasidone Hydrochloride Generics Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care Settings
  • 13.3. Hospitals

14. Lurasidone Hydrochloride Generics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Lurasidone Hydrochloride Generics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Lurasidone Hydrochloride Generics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Lurasidone Hydrochloride Generics Market

18. China Lurasidone Hydrochloride Generics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Accord Healthcare
  • 19.6. Alembic Pharmaceuticals
  • 19.7. Alkem Laboratories
  • 19.8. Amneal Pharmaceuticals
  • 19.9. Annora Pharma
  • 19.10. Aurobindo Pharma
  • 19.11. Camber Pharmaceuticals
  • 19.12. Chartwell Rx
  • 19.13. Cipla
  • 19.14. Dr. Reddy's Laboratories
  • 19.15. Emcure Pharmaceuticals
  • 19.16. Heritage Pharma Avet
  • 19.17. Icon Life Sciences
  • 19.18. Intas Pharmaceuticals
  • 19.19. Invagen Pharmaceuticals
  • 19.20. Jubilant Generics
  • 19.21. Linux Laboratories
  • 19.22. Lupin
  • 19.23. Macleods Pharmaceuticals
  • 19.24. MSN Laboratories
  • 19.25. Sun Pharmaceutical Industries
  • 19.26. Teva Pharmaceutical Industries
  • 19.27. Torrent Pharmaceuticals
  • 19.28. Zydus Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ORALLY DISINTEGRATING TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ORALLY DISINTEGRATING TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ORALLY DISINTEGRATING TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 20 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 20 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 20 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 40 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 40 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 40 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 60 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 60 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 60 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 80 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 80 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 80 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BLISTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BLISTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BLISTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BOTTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BOTTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BOTTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BIPOLAR DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BIPOLAR DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BIPOLAR DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 123. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 124. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 144. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 145. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 151. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 152. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)